A new study published in The Lancet Digital Health suggests that biological age of different organs could predict a person's risk of diseases such as cancer, dementia, and heart disease than their actual chronological age. The research analyzed long-term data from Whitehall II study, which had been followed by over 10,000 British adults for more than 35 years.

The blood plasma samples were collected between 1997 and 1999 from participants between ages 45 to 69. Researchers have now examined a follow up data from 6,235 participants, who were by then aged 65 to 89. This was done to see how aging of specific organ may correlate with the development of diseases over two decades.

What Organs Were Studied?

The study measured the biological age of nine key organs, including:

• Heart
• Blood vessels
• Liver
• Immune system
• Pancreas
• Kidneys
• Lungs
• Intestines
• Brain

The researchers were able to find that different organs aged at different rates in different people. In many of the cases multiple organs showed signs of faster aging within the same individual. What is important to note is that those with accelerated aging in certain organs had a higher risk of developing 30 out of the 40 age-related diseases the study had tracked.

Organ Aging And Disease Risk

Some organ-disease connections were expected—people with rapidly aging lungs were more likely to develop respiratory diseases, and those with aging kidneys had an increased risk of kidney-related conditions. However, the study also found less obvious associations.

For example, individuals with fast-aging kidneys were more prone to diseases in other organs, such as the liver and pancreas. Additionally, multiple fast-aging organs were linked to an increased risk of kidney disease.

One of the most surprising findings was that dementia risk was not best predicted by an aging brain but rather by the immune system’s biological age. This suggests that factors such as chronic inflammation and immune health may play a critical role in neurodegenerative diseases.

What Is Organ Specific Blood Tests?

The study also highlights the important of the potential of developing blood tests that could assess the biological age of specific organs. Unlike previous complex methods that measured the organ health, this new approach could make things simple to detect early signs of disease.

The leader author of the study Mika Kivimaki, who is also a professor at the University College London's Faculty of Brain sciences pointed out that such tests could be helpful when it comes to guiding personalized healthcare. In a news release, Kivimaki said, "They could advise whether a person needs to take better care of a particular organ and potentially provide an early warning signal that they may be at risk of a particular disease."

The study reinforces the idea that aging does not affect all organs equally and that looking beyond chronological age could offer better insights into disease prevention. By understanding which organs are aging more rapidly, medical professionals may be able to recommend targeted interventions for individuals at higher risk of specific conditions. Future advancements in organ-specific blood testing could revolutionize how we detect and manage age-related diseases, potentially leading to more personalized healthcare strategies.

Chronic kidney disease is a disease whereby the patient's kidneys progressively lose their capacity to filter wastes and excessive fluids from the blood stream.

Since kidney damage develops slowly, many individuals might not experience any signs in the early stages of the disease. It is therefore critical for individuals to know about the stages of CKD in order to appreciate the significance of kidney monitoring and timely medical intervention.

Stage 1: Mild Kidney Damage

At stage 1, patients' kidney functions will be relatively normal (eGFR level of 90 or more). However, there will be some indication of kidney damage for example presence of protein in urine. Individuals usually show no symptoms. Controlling diseases like diabetes and high blood pressure can delay progression of CKD.

Stage 2: Mild Loss of Function

This CKD stage is indicated by an eGFR level of 60 – 89 as well as kidney damage. There will probably be no symptoms or very mild symptoms at this stage.

Also read: US CDC Says COVID ‘Growing’ In Nearly Every State: What You Should Know

Stage 3: Moderate Loss of Kidney Function

This stage reflects the moderate loss of kidney function and features an eGFR ranging from 30-59. It normally involves two sub-stages that can be either 3a or 3b. Some of the symptoms of kidney failure can be fatigue, swelling of legs or ankles, changes in urination, or hypertension.

Stage 4: Loss of Kidney Function Is Severe

The fourth stage means that there is a severe loss of kidney functionality, which can be measured by eGFR of 15-29. It normally entails such symptoms as vomiting, swelling, tiredness, or changes in appetite. Health specialists discuss the possibilities of treatment of end-stage kidney disease with their clients and prepare them for getting a new kidney.

Also read: US Woman Paralyzed After Potassium Mistakenly Given During Knee Replacement Surgery

Stage 5: Kidney Failure

Stage 5 is indicated by eGFR being below 15 or the inability of kidneys to perform their functions properly. Waste products and extra fluids can accumulate in the blood and cause life-threatening conditions. Depending on the condition of a patient, the treatments may include dialysis, kidney transplantation, or supportive therapy.

Maintaining Good Kidney Function

The progression of CKD may not always be swift and early detection can make all the difference. The management of blood pressure and sugar, heeding medical advice, living a healthy lifestyle and regular medical check-ups can help preserve kidney functions. If anyone experiences consistent swelling, alteration in urinary habits or feels unusually tired among other symptoms, they should visit a Nephrologist.

Obstructive hypertrophic cardiomyopathy (oHCM) remains one of the most misunderstood cardiac conditions, despite being the most common inherited cardiomyopathy. Misconceptions around the disease often lead to fear, delayed diagnosis, and hesitation in seeking appropriate medical care.

While oHCM has historically been associated with sudden cardiac death, particularly in young athletes, advances in diagnosis and treatment have significantly transformed its management. Today, with early diagnosis and appropriate treatment, many patients can lead active and fulfilling lives.

Understanding the facts is essential, not only for patients living with the condition, but also for families, caregivers, and the wider community. Separating myths from medical evidence can help ensure timely diagnosis, informed treatment decisions, and better long-term outcomes.

Understanding oHCM

Obstructive hypertrophic cardiomyopathy (oHCM) is a form of hypertrophic cardiomyopathy (HCM)—an inherited heart muscle disorder caused by genetic mutations that affect heart muscle structure and function. These changes cause the heart muscle to become abnormally thick, most commonly affecting the wall (septum) between the two lower chambers of the heart.

In nearly two-thirds of patients with hypertrophic cardiomyopathy, the thickened heart muscle can block the flow of blood leaving the heart—a condition known as obstructive HCM (oHCM). As a result, the heart must work harder to pump blood throughout the body, often leading to symptoms such as breathlessness, chest pain, fatigue, dizziness, palpitations, or fainting during physical activity.

Myth: A diagnosis of oHCM inevitably leads to sudden death.

Fact: While oHCM was once primarily recognised for its association with sudden cardiac death, advances in medical science have significantly improved patient outcomes.

With timely diagnosis, appropriate medical care, and ongoing monitoring, many people with oHCM can lead active lives with a good quality of life and a near-normal life expectancy. Regular follow-up helps assess disease progression and guides individualized care over time.

Myth: People with oHCM need to avoid physical activities

Fact: Complete avoidance of physical activity is no longer recommended for most patients.

Although high-intensity competitive sports may not be suitable for everyone with oHCM, mild-to-moderate exercise is generally encouraged and offers important cardiovascular benefits. Exercise recommendations should always be individualised after a comprehensive assessment by a cardiologist, taking into account symptoms, severity of obstruction, and overall risk profile.

Myth: Diet and lifestyle are the primary causes of oHCM.

Fact: oHCM is a genetic condition. It is not a lifestyle disease.

Unlike heart conditions caused by high blood pressure, diabetes, or high cholesterol, oHCM develops because of inherited genetic mutations affecting heart muscle proteins. Healthy lifestyle choices remain important for overall cardiovascular health, but they do not cause or prevent the condition itself. Because the disease often runs in families, screening of close relatives may also be recommended.

Myth: Every patient with oHCM will require surgical treatment.

Fact: Surgery is only one of several available treatment options. Care is individualized, and the most appropriate approach depends on each patient's symptoms and clinical condition.

Myth: oHCM cannot go unnoticed.

Fact: The condition can remain silent for years. Some individuals carrying the genetic mutation never develop symptoms, while others experience mild or intermittent symptoms that may be attributed to more common conditions. Typical symptoms include:

• Shortness of breath
• Chest pain
• Fatigue
• Palpitations
• Dizziness or light-headedness
• Fainting, particularly during or after exercise

Given this variability, individuals with persistent symptoms or a family history of cardiomyopathy or sudden cardiac death should undergo appropriate cardiac evaluation.

Myth: Medication can cure the disease

Fact: Advances in treatment have significantly improved disease management, helping many patients lead healthier and more active lives. While current therapies focus on controlling symptoms and reducing complications, ongoing research continues to expand treatment possibilities.

Treatment aims to reduce symptoms, improve blood flow, minimize obstruction, and lower the risk of complications such as abnormal heart rhythms and heart failure. Long-term follow-up remains an important part of care, allowing treatment to be adjusted as the condition evolves.

Myth: There's no benefit to diagnosing oHCM early

Fact: Early diagnosis can make a significant difference. Because oHCM symptoms often resemble those of other conditions, timely testing is important—especially for those with a family history of the disease. Early detection can help patients access appropriate treatment, manage symptoms effectively, and reduce the risk of complications.

Why Awareness Matters

The understanding and management of obstructive hypertrophic cardiomyopathy have evolved considerably over the past decade. Although it remains a lifelong condition, it is no longer viewed through the lens of fear alone. Advances in medical therapies, improved diagnostic tools, and personalized treatment strategies have changed the outlook for many patients.

By challenging common myths and promoting awareness, more individuals can be diagnosed earlier, receive appropriate treatment, and live healthier, more active lives with confidence.

(Dr. Daljeet Kaur, Cardiac Electrophysiologist at AIG Hospital, Hyderabad)

It is a common belief that metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as non-alcoholic fatty liver disease (NAFLD)—is primarily associated with diet, sedentary lifestyles, and obesity. However, there are other factors as well that affect this aspect. Post-menopausal women experience a significantly higher incidence and faster progression of fatty liver disease, even when maintaining a stable body weight.

In Pre-menopausal women, estrogen plays a central role in metabolism by promoting healthy fat accumulation in subcutaneous tissue (below the skin) rather than around internal organs; it also increases insulin sensitivity and suppresses liver inflammation.

After menopause, when estrogen levels drop, this protective function is lost; there is redistribution of fat leading to more fat accumulation around internal organs, including the liver, thus leading to increased chances of NAFLD and also increasing insulin resistance. Needless to say, with age, our metabolic rate also goes down, which also plays a role in this.

The important part lies not only in understanding the above but in going further in early detection and prevention of menopause associated NAFLD. As we know, fatty liver is a silent disease and often does not cause any signs and symptoms till a very advanced stage.

First and foremost is to change lifestyle with advancing age, changing both the dietary habits and physical activity. Regular screening and monitoring are warranted with blood tests, routine metabolic panels, keeping a tab on weight, sugar, and cholesterol levels, and a basic ultrasound of the abdomen. For someone already diagnosed with second or third stage fatty liver, a simple non-invasive FibroScan can help monitor and assess the response to treatment.

Coming to the treatment part of NAFLD in post-menopausal women, being primarily a lifestyle disease, the core of management also lies in managing lifestyle. Medicines are available for treating and controlling NAFLD in conjunction with lifestyle management. Hormone replacement therapy (HRT), when initiated early in post-menopausal women for symptomatic relief, may offer secondary benefits by maintaining metabolic health. However, HRT should always be initiated after proper evaluation and expert guidance.

NAFLD is a silent epidemic and primarily a lifestyle disease; knowing about it and knowing the triggering and precipitating factors helps with understanding and prevention better. Menopause, being a natural biological phenomenon in every female’s life, makes it essential for us to know how it affects our liver health and overall health as well.